Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study
- PMID: 27599521
- DOI: 10.1136/gutjnl-2016-311854
Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study
Abstract
Background and aim: Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome, was associated with subclinical atherosclerosis in many cross-sectional studies, but the prospective association between NAFLD and the progression of atherosclerosis has not been evaluated. This study was conducted to evaluate the association between NAFLD and the progression of coronary atherosclerosis.
Methods: This retrospective cohort study included 4731 adult men and women with no history of cardiovascular disease (CVD), liver disease or cancer at baseline who participated in a repeated regular health screening examination between 2004 and 2013. Fatty liver was diagnosed by ultrasound based on standard criteria, including parenchymal brightness, liver-to-kidney contrast, deep beam attenuation and bright vessel walls. Progression of coronary artery calcium (CAC) scores was measured using multidetector CT scanners.
Results: The average duration of follow-up was 3.9 years. During follow-up, the annual rate of CAC progression in participants with and without NAFLD were 22% (95% CI 20% to 23%) and 17% (16% to 18%), respectively (p<0.001). The multivariable ratio of progression rates comparing participants with NAFLD with those without NAFLD was 1.04 (1.02 to 1.05; p<0.001). The association between NAFLD and CAC progression was similar in most subgroups analysed, including in participants with CAC 0 and in those with CAC >0 at baseline.
Conclusions: In this large cohort study of adult men and women with no history of CVD, NAFLD was significantly associated with the development of CAC independent of cardiovascular and metabolic risk factors. NAFLD may play a pathophysiological role in atherosclerosis development and may be useful to identify subjects with a higher risk of subclinical disease progression.
Keywords: CARDIOVASCULAR DISEASE; FATTY LIVER; FIBROSIS; ULTRASONOGRAPHY.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Comment in
-
Non-alcoholic fatty liver disease as driving force in coronary heart disease?Gut. 2017 Feb;66(2):213-214. doi: 10.1136/gutjnl-2016-312891. Epub 2016 Sep 27. Gut. 2017. PMID: 27679492 No abstract available.
Similar articles
-
Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study.Gut. 2019 Sep;68(9):1667-1675. doi: 10.1136/gutjnl-2018-317666. Epub 2018 Nov 24. Gut. 2019. PMID: 30472683
-
Nonalcoholic Fatty Liver Disease Is Associated With Coronary Artery Calcification Development: A Longitudinal Study.J Clin Endocrinol Metab. 2016 Aug;101(8):3134-43. doi: 10.1210/jc.2016-1525. Epub 2016 Jun 2. J Clin Endocrinol Metab. 2016. PMID: 27253666
-
Higher association of coronary artery calcification with non-alcoholic fatty liver disease than with abdominal obesity in middle-aged Korean men: the Kangbuk Samsung Health Study.Cardiovasc Diabetol. 2015 Jul 15;14:88. doi: 10.1186/s12933-015-0253-9. Cardiovasc Diabetol. 2015. PMID: 26169265 Free PMC article.
-
Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis.Rev Esp Enferm Dig. 2015 Jan;107(1):10-6. Rev Esp Enferm Dig. 2015. PMID: 25603326 Review.
-
Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis.Open Heart. 2021 Dec;8(2):e001850. doi: 10.1136/openhrt-2021-001850. Open Heart. 2021. PMID: 34933963 Free PMC article.
Cited by
-
Solitary kidney and risk of chronic kidney disease.Eur J Epidemiol. 2019 Sep;34(9):879-888. doi: 10.1007/s10654-019-00520-7. Epub 2019 Apr 25. Eur J Epidemiol. 2019. PMID: 31025238
-
A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL.Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):503-516. doi: 10.1007/s00259-021-05447-4. Epub 2021 Jun 21. Eur J Nucl Med Mol Imaging. 2022. PMID: 34155537
-
Elevated AIP is associated with the prevalence of MAFLD in the US adults: evidence from NHANES 2017-2018.Front Endocrinol (Lausanne). 2024 May 14;15:1405828. doi: 10.3389/fendo.2024.1405828. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38808115 Free PMC article.
-
Metabolic dysfunction-associated fatty liver disease as a mediator of urolithiasis risk: evidence from cross-sectional and genetic studies.Int J Med Sci. 2025 Jan 21;22(4):764-774. doi: 10.7150/ijms.106824. eCollection 2025. Int J Med Sci. 2025. PMID: 39991773 Free PMC article.
-
The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque.BMC Cardiovasc Disord. 2023 Nov 11;23(1):554. doi: 10.1186/s12872-023-03580-6. BMC Cardiovasc Disord. 2023. PMID: 37951879 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical